Background-In fibrosing alveolitis activation of lung fibroblasts is the decisive event in the pathogenetic sequence leading to pulmonary fibrosis. Fibroblast stimulating activity was measured in bronchoalveolar lavage (BAL) fluid to assess its relationship to the activity of fibrosing alveolitis. Methods-Nine control subjects and 40 patients with fibrosing alveolitis caused by idiopathic pulmonary fibrosis (n = 22) or pulmonary involvement in systemic sclerosis (n = 18) were studied. All patients were followed up by lung function testing for a minlimum of six months (mean (SE) 13-3 (1.4) months). Twenty five patients received inmunosuppressive therapy and 15 refused. At the beginning of follow up BAL was performed and, as a possible indicator of fibroblast stimulating mediators within the lungs, chemotactic migration of cultured human fibroblasts elicited by native BAL fluid was measured in Boyden-type chambers and expressed as a percentage of the chemoattractant effect of 25 nglml platelet derived growth factor. The procollagen III peptide level in BAL fluid served as a marker for collagen synthesis. Results-Chemoattractant activity was elevated in the patients with idiopathic pulmonary fibrosis and systemic sclerosis compared with the control group, (mean (SE) 56-4% (8-5%)) and 72-3% (16.3%) v 12-6% (4.0%). Chemoattractant activity was inversely correlated with total lung capacity (TLC) (r = -0.45) and with vital capacity (VC) (r = -033). Procollagen III peptide concentrations in BAL fluid and chemoattractant activity were not significantly correlated. For further evaluation chemoattractant activity of 36% (mean value of controls + 2 SD) was used to separate normal (<36%) from elevated ( >36%) activity.
Abstract
Background-In fibrosing alveolitis activation of lung fibroblasts is the decisive event in the pathogenetic sequence leading to pulmonary fibrosis. Fibroblast stimulating activity was measured in bronchoalveolar lavage (BAL) fluid to assess its relationship to the activity of fibrosing alveolitis. Methods-Nine control subjects and 40 patients with fibrosing alveolitis caused by idiopathic pulmonary fibrosis (n = 22) or pulmonary involvement in systemic sclerosis (n = 18) were studied. All patients were followed up by lung function testing for a minlimum of six months (mean (SE) 13-3 (1.4) months). Twenty five patients received inmunosuppressive therapy and 15 refused. At the beginning of follow up BAL was performed and, as a possible indicator of fibroblast stimulating mediators within the lungs, chemotactic migration of cultured human fibroblasts elicited by native BAL fluid was measured in Boyden-type chambers and expressed as a percentage of the chemoattractant effect of 25 nglml platelet derived growth factor. The procollagen III peptide level in BAL fluid served as a marker for collagen synthesis. Results-Chemoattractant activity was elevated in the patients with idiopathic pulmonary fibrosis and systemic sclerosis compared with the control group, (mean (SE) 56-4% (8-5%)) and 72-3% (16.3%) v 12-6% (4.0%). Chemoattractant activity was inversely correlated with total lung capacity (TLC) (r = -0.45) and with vital capacity (VC) (r = -033). Procollagen III peptide concentrations in BAL fluid and chemoattractant activity were not significantly correlated. For further evaluation chemoattractant activity of 36% (mean value of controls + 2 SD) was used to separate normal (<36%) from elevated ( >36%) activity.
At the end of follow up, untreated patients with high chemoattractant activity (> 36%) showed a significant reduction of VC, TLC, and exercise arterial oxygen tension (Pao,) and a small decrease in carbon monoxide transfer factor (TLCO), whereas a significant improvement in VC, TLC, and TLCO and a small increase of exercise Pao, occurred in treated patients with high chemoattractant activity. Patients with low chemoattractant activity (<36%) showed no consistent change in lung function measurements, irrespective of treatment. In contrast, lung function results and differential cell counts in BAL fluid failed to identify progressive disease. Conclusions-In patients with fibrosing alveolitis the chemoattractant activity of BAL fluid seems to be an independent indicator of lung fibroblast stimulating activity providing relevant information about disease activity, and may help to improve the clinical management of these patients. or for fibroblast growth inducing activities."-15 We hoped that a better measure of the contribution of fibroblasts to the development of fibrosing alveolitis may improve the understanding and management of this process. We therefore measured the chemoattractant activity of native BAL fluid for cultured human fibroblasts as a possible indicator of profibrotic activity within the lungs. The data were compared with the cytological finding of the BAL fluid, procollagen III peptide levels, lung function values, and clinical appearance of the patients.
Methods

STUDY POPULATION
Control group
The control group consisted of nine nonsmoking volunteers (two women, seven men; mean age 43-3 (4 6) years) without pulmonary disease who underwent fibreoptic bronchoscopy and BAL for the purposes of this study ( (2 6 ) years) had pulmonary disease from systemic sclerosis which was diagnosed from the clinical picture and from symptoms in agreement with previously proposed criteria.'920 All were non-smokers or had given up smoking for at least two years (n = 3). The study protocol was approved by the local ethical committee. Informed consent was obtained from the control subjects and patients. FOLLOW UP AND TREATMENT All patients were followed up for at least six months (mean (SE) 13-2 (1.5) months).
Complete lung function tests, as described above, were performed at the end of the follow up period in each patient.
Immunosuppressive treatment was offered to all patients. After discussion of the possible benefits and side effects of this therapy 15 patients refused treatment but agreed to have control investigations to follow the course of their disease. In 25 patients immunosuppressive treatment was started with 1 0-1 5 mg/kg prednisolone daily for 8-12 weeks. Response to treatment was assessed by pulmonary function tests. If improvement or stabilisation occurred the corticosteroid dose was tapered by 10 mg/week to a maintenance dose of 10-20 mg/day. If deterioration occurred despite the high dose of prednisolone used (decline of VC or TLCO by more than 10%, or decrease of exercise Pao2 by 5 mm Hg or more, or both), cyclophosphamide (2-3 mg/kg) was added. The dose of cyclophosphamide was slowly reduced to a maintenance dose of 0-5-1 0 mg/kg after 4-6 months. The prednisolone maintenance dose remained at 10-20 mg daily, irrespective of additional cyclophosphamide treatment. At the end of the study 13 patients received prednisolone only and 12 patients were on treatment with prednisolone plus cyclophosphamide.
BRONCHOALVEOLAR LAVAGE (BAL) BAL was performed in all patients at their first presentation as previously described. '6 They had been off immunosuppressive drugs for at least three months.
A fibreoptic bronchoscope was wedged in a subsegmental bronchus of the middle lobe or lingula and five serial infusions and aspirations were performed, each of 20 ml sterile saline (0 9% NaCl). The recovered fluid (mean (SE) 45-8 (2 7) ml) was pooled, filtered through sterile gauze, centrifuged at 300 g for 10 minutes, and the supernatants stored at -70°C. Total cell counts were measured by a Coulter counter. Mean percentages of alveolar macrophages, neutrophils, eosinophils, lymphocytes, and mast cells were determined from slide preparations stained with the May-Grinwald-Giemsa stain, counting 600 cells.
PROCOLLAGEN III PEPTIDE MEASUREMENTS
Procollagen III amino terminal peptide related antigen (P-III-P) was determined in native BAL fluid using a radioimmunoassay kit (RIA-gnost P III P, Behringwerke AG, Marburg, Germany), based on the method of Rohde et al. 21 The detection limit of the assay was 0-1 units/ml P-III-P. The antibody employed detects the whole P-III-P proteins but not P-III-P fragments and does not cross react with type I collagen, type I procollagen, 7S collagen, laminin, or fibronectin according to the manufacturer. The value of the detection limit was used for the calculations when procollagen III peptide was undetectable in the BAL fluid.
Results were expressed as units of procollagen III peptide per ml native BAL fluid since no satisfactory reference component for normalisation of BAL (22) SSC (18) CAA < 36%
CAA > 36%
IPF (6) SSC (7) IPF (16) IPF (1) IPF (5) IPF (7) SSC (5) SSC (2) SSC (2) A B 5. In all patients in group C (high chemoattractant activity, no treatment) TLC declined during follow up, whereas in group D (high chemoattractant activity, immunosuppressive therapy) TLC improved or stabilised in 15 of 18 patients (83%) during follow up.
Discussion
The crucial role of fibroblasts in the pathogenesis of interstitial lung disease has SSC (11) At present no satisfactory method exists to assess, at any given time, the IPF (9) activity of these cells in vivo. In this study we SSC (9) measured fibroblast attracting activity in D native BAL fluid as a possible indicator of group.bmj.com on June 13, 2017 -Published by http://thorax.bmj.com/ Downloaded from Table 2 Mean (SE) results in patients with low and high chemoattractant activity (CAA). 
CAA-chemoattractant activity; PDGF-platelet derived growth factor; VC-vital capacity; TLC-total lung capacity; TLco-carbon monoxide transfer factor; TCC-total cell count; T4/T8 ratio-quotient of T helper to T suppressor lymphocytes; protein-total protein concentration in BAL fluid; P-f-P-amino terminal procollagen-i-peptide related antigen; *7-5 mm Hg = 1 kPa; tP < 0'05 v groups B, C, and D. T, 80 '7 (6'9) 70-1 75'2 (9'6)t 
